Abstract

Teleflex will release its quarterly results on February 26, 2026 Pre-Market, with investors watching revenue growth, margins, and EPS momentum after recent guidance changes and shifting analyst sentiment.

Market Forecast

Consensus expectations point to Teleflex delivering revenue of 919.30 million in the current quarter, implying 13.04% year-over-year growth, with adjusted EPS estimated at 3.73, down 3.30% year-over-year; EBIT is forecast at 217.14 million, down 1.34% year-over-year, while consensus margin forecasts were not disclosed in the available dataset. The main business outlook centers on sustaining volume and pricing across North American consumable categories, where gross profitability in the prior quarter remained solid despite GAAP net loss. Interventional North America remains the most prominent revenue contributor at 266.41 million last quarter; year-over-year detail for this segment was not disclosed in the dataset, but it continues to anchor overall performance.

Last Quarter Review

Teleflex reported revenue of 913.02 million, a gross profit margin of 49.53%, GAAP net profit attributable to the parent company of -409.00 million, a net profit margin of -44.78%, and adjusted EPS of 3.67, which rose 5.16% year-over-year. A notable swing in profitability occurred quarter-on-quarter, with net profit down 433.57%, highlighting the impact of significant non-operating items that overshadowed a relatively resilient gross profit profile. Main business highlights: Interventional North America was 266.41 million, Vascular North America was 191.02 million, Surgical North America was 122.88 million, Anesthesia North America was 101.45 million, OEM was 80.41 million, All Other was 79.08 million, and Interventional Urology was 71.77 million; year-over-year segment growth rates were not disclosed in the dataset.

Current Quarter Outlook

Main Business Trajectory

Teleflex’s core consumable categories continue to drive revenue scale in North America, and consensus projects total revenue of 919.30 million, implying 13.04% year-over-year growth. That top-line expansion pace is respectable in the context of the company’s prior quarter, where gross margin held at 49.53% and revenue reached 913.02 million despite a sharp GAAP net loss. The current-quarter EPS estimate of 3.73 suggests a modest decline of 3.30% year-over-year, and the EBIT estimate of 217.14 million implies a 1.34% year-over-year decline, indicating that operating efficiency and mix may be pressured even as volumes expand. The gap between the prior quarter’s strong gross margin and negative net margin implies that non-operating items, one-time charges, or below-the-line effects weighed on GAAP profitability; this quarter, investors will be looking for confirmation that those impacts are transitory and that operating trends remain intact. With EBIT expected to be slightly lower year-over-year, cost discipline, manufacturing throughput, and product mix will matter for margin stabilization. The chief near-term test is whether pricing and volume create sufficient operating leverage to offset any lingering cost inflation or portfolio changes. Management’s revenue execution remains the core pillar of the investment case this quarter. Given the prior revenue performance of 913.02 million and the current estimate of 919.30 million, the incremental growth suggests demand resilience across clinical use cases. However, translating that demand into improved EPS will require firm control of SG&A and R&D spend in step with revenue, as well as mitigating any restructuring or divestiture-related noise that could flow through the P&L below the gross line. With adjusted EPS expected lower year-over-year, attention turns to whether margin quality improves on a sequential basis as operating friction eases.

Most Promising Segment: Interventional North America

Interventional North America remains the largest revenue contributor at 266.41 million last quarter, giving it outsized influence on overall results and the perception of execution quality. Its scale creates both opportunity and scrutiny: volume consistency, account retention, and pricing sustainability are key variables that can compound at the consolidated level. The lack of disclosed segment-level year-over-year growth in the dataset limits precision, but the weight of this segment in the mix means that any positive inflection in orders or throughput will be visible in consolidated revenue and operating metrics. The current-quarter narrative will focus on whether clinical demand trends and purchasing dynamics support sustained growth in interventional consumables. Because these products are used in recurring procedural settings, a steady cadence of hospital procurement can underpin top-line momentum even in mixed macro environments. At the same time, any portfolio reshaping or SKU optimization undertaken by management must preserve the segment’s contribution to gross margin while avoiding dilution to EBIT from transition costs or sales channel adjustments. Pricing power and product mix will be critical levers. If Teleflex can tilt utilization toward higher-value configurations while maintaining competitive fulfillment lead times, margin quality can improve even if headline revenue growth moderates from double digits. Conversely, if promotional intensity or contracting concessions are necessary to maintain volume in the near term, EBIT performance could track the consensus expectation for a slight year-over-year decline, reinforcing the importance of execution on cost containment and operational efficiency.

Key Stock Price Drivers This Quarter

Investor sentiment into the print has been shaped by the company’s January 8, 2026 guidance reset, which was followed by a reported 9% pre-market decline, signaling heightened sensitivity to top-line outlooks and the perceived durability of margin recovery. Subsequent analyst actions captured both cautious and constructive interpretations, but the market’s baseline concern has centered on whether margin headwinds from portfolio moves, leadership changes, or restructuring will continue to weigh on EPS near term. The current quarter’s estimates reflect that tension: revenue up 13.04% year-over-year, but EPS down 3.30% and EBIT down 1.34% year-over-year. The first determinant of the stock’s immediate reaction will be revenue versus consensus and any change to full-year guidance. A beat on revenue paired with evidence of sequential margin stabilization could prompt a favorable response even if EPS is near expectations, especially if management indicates that below-the-line impacts have normalized. Conversely, an in-line or modest miss on revenue alongside lingering margin compression would likely validate cautious views and keep the focus on execution risk and portfolio clarity. A second driver is disclosure around non-operating items and the trajectory of GAAP versus adjusted metrics. The prior quarter showed a sharp divergence, with adjusted EPS of 3.67 rising 5.16% year-over-year while GAAP net profit was -409.00 million and the net margin was -44.78%. Clear articulation of the drivers behind that divergence, their expected duration, and steps taken to mitigate future volatility will shape confidence in the quality of earnings. Finally, any commentary on leadership transitions or strategic divestitures and their timeline will influence expectations for operating rhythm through 2026, guiding how investors frame near-term risk versus multi-quarter normalization.

Analyst Opinions

Bearish views constitute the majority within the January 1, 2026 to February 19, 2026 window, with two notable cautious or negative stances versus one positive rating. Bank of America Securities’ Travis Steed maintained an Underperform (Sell) rating in mid-January, citing strategic uncertainty, leadership transition, and slowing growth as the key reasons for sustained caution. This perspective aligns with the market’s reaction to the January guidance cut, where shares reportedly fell 9% pre-market, underscoring concerns that portfolio adjustments and management changes could depress near-term visibility on growth and margin normalization. Cautious commentary has also come from Needham in early January, when the firm maintained a Hold rating and highlighted reduced guidance and margin decline as justification for staying neutral at that time. Even with a later upgrade to Buy in early February, the prevailing sentiment within the January-to-mid-February period leaned toward caution, reflecting a majority view that the near-term earnings trajectory may be constrained by execution factors rather than demand softness alone. The bearish camp has emphasized the importance of clarity on the pace and impact of divestitures, as well as the need for consistent margin performance to validate adjusted EPS durability. From an analytical perspective, the bearish majority expects revenue growth to be insufficient to fully offset incremental costs or one-time effects in the near term, particularly given consensus forecasts for adjusted EPS at 3.73, down 3.30% year-over-year, and EBIT at 217.14 million, down 1.34% year-over-year. These projections suggest operating leverage may be muted this quarter, keeping valuation sensitivity high to margin disclosures and guidance quality. The GAAP versus adjusted disconnect last quarter, with a -409.00 million GAAP net result against a 3.67 adjusted EPS, reinforces the need for detailed reconciliation and credible steps to reduce below-the-line volatility. Bearish analysts are likely to focus on three validation points in the report. First, whether revenue growth of 13.04% year-over-year comes with a sequentially improving margin profile, hinting at normalization after the prior quarter’s non-operating drag. Second, whether management provides a firm, time-bound roadmap for portfolio actions and leadership transitions that removes ambiguity around medium-term earnings power. Third, whether operating expense trends align with stabilization targets to support EPS recovery as one-time effects fade. If these elements are not substantively addressed, the bearish case anticipates continued skepticism in the stock’s near-term risk/reward, even if demand indicators remain steady across core consumable categories. Within this framework, the majority view does not challenge the durability of end-market utilization but underscores that earnings quality and strategic clarity are essential to shifting sentiment. While revenue growth is expected this quarter, the distribution of that growth across segments and its translation into EBIT and EPS will determine whether the stock can re-rate. Until the company demonstrates consistent margin normalization and reduces reliance on adjustments to bridge GAAP-to-adjusted gaps, the bearish majority remains focused on execution and guidance as the central catalysts for the shares.